Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy
Phase 4
Completed
- Conditions
- Bronchoscopy
- Registration Number
- NCT00394537
- Lead Sponsor
- Rabin Medical Center
- Brief Summary
Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.
We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- All patients over 18 years old undergo fiberoptic bronchoscopy in our unit
Exclusion Criteria
- inability or refusal to give informed consent
- bronchoscopy through an artificial airway
- intolerance or allergy to the study drug
- bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
- pregnancy,
- concomitant treatment with diltiazem or verapamil
- intention to use propofol as the sedative agent for bronchoscopy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Heart Rate Systolic Blood Pressure Diastolic Blood Pressure Rate pressure product (HR*SBP/100)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Rabin Medical Center🇮🇱Petach Tikva, Israel